CTSH Volume Alert - CTSH 53.07 Cognizant Technology

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
CTSH Volume Alert - CTSH 53.07 Cognizant Technology Solutions $CTSH Hit a high of 53.44 Currently 11:15 Last price 53.07 -0.58 -1.08% With a day low of 52.89 and a current volume of 2,511,161.

CTSH Cognizant Technology Solutions Recent Headline News

One Reason Cognizant Technology Solutions (CTSH) Stock Is Declining Today
at The Street - Tue Nov 11, 9:09AM CST
Cognizant Technology Solutions (CTSH) stock is lower after the IT company was downgraded to 'neutral' from 'buy' at UBS.
CTSH: 53.00 (-0.65)

Watch for Shares of Cognizant Technology Solutions (CTSH) to Approach Support at $52.80
Comtex SmarTrend(R) - Tue Nov 11, 9:00AM CST
Cognizant Technology Solutions (NASDAQ:CTSH) has opened bearishly below the pivot of $53.73 today and has reached the first level of support at $53.23. Investors may be interested in a cross of the next downside pivot targets of $52.80 and $51.87.
CTSH: 53.00 (-0.65)

Downgrade Alert for Cognizant Technology Solutions (CTSH)
Comtex SmarTrend(R) - Tue Nov 11, 7:05AM CST
Cognizant Technology Solutions (NASDAQ:CTSH) was downgraded from Buy to Neutral at UBS today. The stock closed yesterday at $53.65 on volume of 6.2 million shares, above average daily volume of 5.4 million. Cognizant Technology Solutions (NASDAQ:CTSH) defies analysts with a current price ($53.65) 3.9% above its average consensus price target of $51.58. The stock should discover initial support at its 200-day moving average (MA) of $48.15 and subsequent support at its 50-day MA of $45.78.
CTSH: 53.00 (-0.65)

Cognizant Partners With CFA Institute to Enhance Financial Knowledge of Its Business Process Services Talent
Marketwired - Mon Nov 10, 7:00PM CST
CFA Institute today announced that Cognizant has become the first corporation in the global technology and business process services industry to adopt the Claritas Investment Certificate program, a comprehensive global program designed to give all professional disciplines in financial services outside of investment roles a clear understanding of the investment industry and their professional responsibilities within it.
CTSH: 53.00 (-0.65)

Third Quarter Results, Dividend Declarations, and New Services - Research Reports on LinkedIn, FireEye, CrownCastle, Cognizant and Level 3
PR Newswire - Mon Nov 10, 7:55AM CST
Today, Analysts Review released its research reports regarding LinkedIn Corporation (NYSE: LNKD), FireEye, Inc. (NASDAQ: FEYE), Crown Castle International Corp. (NYSE: CCI), Cognizant Technology Solutions Corporation (NASDAQ: CTSH) and Level 3 Communications, Inc. (NYSE: LVLT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7829-100free.
CCI: 79.76 (-0.15), LVLT: 46.52 (+0.23), FEYE: 32.45 (+0.06), LNKD: 228.50 (-0.75), CTSH: 53.00 (-0.65)

Do You Have The Patience To Be A Successful Value Investor?
Chuck Carnevale - at Seeking Alpha - Fri Nov 07, 2:24PM CST

LMT: 187.06 (+0.07), HPQ: 36.75 (-0.15), CTSH: 53.00 (-0.65), TUP: 64.54 (+0.02)

Company News for November 06, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 9:10AM CST
Companies in the News are: ACT,CTSH,COV,TW
ACT: 242.63 (-3.10), COV: 93.45 (-0.19), CTSH: 53.00 (-0.65), TW: 113.52 (-1.15)

Cognizant Technology
at Investor's Business Daily - Wed Nov 05, 5:41PM CST
Cognizant Technology (CTSH) Q3 EPS fell 9.4% to 58 cents, missing estimates by a penny. Revenue jumped 11.9% to $2.581 bil, passing expectations for $2.567 bil. The IT services provider sees full-year EPS of at least $2.57, above projections for...
CTSH: 53.00 (-0.65)

India In Focus: Cognizant Breaks Out, Tata Bases
at Investor's Business Daily - Wed Nov 05, 4:42PM CST
Healthy third-quarter results sent Cognizant Technologies (CTSH) up more than 8% Wednesday and placed investor attention on a number of India-related stocks. Cognizant, which began as the Indian IT arm of Dunn & Bradstreet, is a world citizen....
F: 14.16 (+0.16), IBN: 58.50 (+0.51), HDB: 51.73 (-0.08), GM: 31.22 (+0.10), FCAU: 11.43 (+0.38), CTSH: 53.00 (-0.65), TTM: 45.64 (-0.90)

Cognizant Has Solid Quarter, Bullish on Health Care, IT Spending
at The Street - Wed Nov 05, 3:59PM CST
Cognizant Technology Solutions came in with solid third-quarter earnings and provided favorable guidance for the fourth quarter and fiscal year 2014.
IBM: 162.97 (-0.52), INFY: 67.15 (-0.61), CTSH: 53.00 (-0.65)

Cognizant Technology Solutions Rises 8.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Nov 05, 3:55PM CST
Cognizant Technology Solutions (NASDAQ:CTSH) traded in a range yesterday that spanned from a low of $50.45 to a high of $52.60. Yesterday, the shares gained 8.1%, which took the trading range above the 3-day high of $49.46 on volume of 10.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CTSH: 53.00 (-0.65)

Cognizant Tech Solutions (CTSH) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Wed Nov 05, 2:38PM CST
The following Cognizant Tech Solutions (CTSH) conference call took place on November 5, 2014, 08:00 AM ET. This is a transcript of that earnings call:
CTSH: 53.00 (-0.65)

Cognizant Technology Solutions' (CTSH) CEO Francisco D'Souza on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 12:18PM CST

CTSH: 53.00 (-0.65)

Cognizant CFO Karen McLaughlin Says Health Care, the Cloud Are Key to Growth
at The Street - Wed Nov 05, 12:10PM CST
Cognizant beat predictions on earnings, but now faces the challenge of becoming a major player in health care IT.
MCK: 202.50 (+1.22), WDAY: 94.48 (-0.68), CTSH: 53.00 (-0.65), HNT: 47.92 (+0.41), CERN: 63.07 (-0.35), CRM: 63.90 (-0.55)

Cognizant Technology Beats on Q3 Earnings and Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:00PM CST
Cognizant Technology Solutions Corp. (CTSH), reported third-quarter 2014 earnings of 66 cents per share, which beat the Zacks Consensus Estimate.
WIT: 12.35 (-0.11), INFY: 67.15 (-0.61), CTSH: 53.00 (-0.65), ACN: 83.88 (-0.28)

Cognizant (CTSH) Stock Soars on Increased Fourth Quarter Earnings Outlook
at The Street - Wed Nov 05, 11:14AM CST
Cognizant (CTSH) stock is rising after the company raised its fourth quarter earnings and revenue guidance, following its better than expected third quarter earnings this morning.
CTSH: 53.00 (-0.65)

Today's Unusual Social Activity Stock: Cognizant Technology Solutions (CTSH)
at The Street - Wed Nov 05, 8:59AM CST
Trade-Ideas LLC identified Cognizant Technology Solutions (CTSH) as an unusual social activity candidate
CTSH: 53.00 (-0.65)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 8:16AM CST

TTPH: 22.97 (-0.91), AWAY: 30.53 (+0.87), PHMD: 2.73 (-0.01), ROYT: 9.75 (-0.14), VG: 3.73 (+0.13), MEMP: 16.66 (-0.21), MACK: 8.66 (-0.04), ATVI: 20.58 (-0.34), NUS: 40.62 (-1.02), SSYS: 102.13 (-2.76), EOG: 98.62 (+0.12), CLNY: 24.59 (+0.24), CRTO: 36.82 (+0.37), IBIO: 1.16 (-0.07), NICE: 45.97 (+0.49), VPCO: 1.60 (-0.15), ZU: 29.27 (+0.44), EXEL: 1.79 (unch), ANV: 1.14 (+0.04), FEYE: 32.45 (+0.06), JIVE: 6.61 (+0.17), TRIP: 69.85 (-3.04), WLT: 2.94 (-0.22), YOD: 2.67 (unch), CHUY: 22.66 (-0.60), ANR: 2.58 (-0.06), NG: 2.89 (+0.20), AEZS: 0.61 (-0.01), ARIA: 6.37 (+0.08), CTSH: 53.00 (-0.65)

Cognizant +5.2% on Q3 beat, strong Q4 guidance
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 7:20AM CST

CTSH: 53.00 (-0.65)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 221

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 79

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 189

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 118

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 85

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 129

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 389

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 0

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 159

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 166

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading

Top 5 Most Recently Viewed Articles

Trex Company Investigated for Securities Fraud: What Investors Need to Know

Updated Category News Views 181

Trex Company, Inc. Under Scrutiny for Securities Violations Trex Company, Inc. (NYSE: TREX) is currently facing an investigation regarding potential violations of federal securities laws. This inquiry is being conducted by the Law Offices of Howard G. Smith. The investigation stems from the company's recent financial disclosures, which raised concerns among investors....

Continue Reading
IRONMAN and Experience Oman Join Forces for Global Sports

Updated Category News Views 297

IRONMAN Partners with Experience Oman for a Dynamic Future The recent alliance between IRONMAN and Experience Oman marks a groundbreaking development in the realm of sports tourism. This partnership sets the stage for the prestigious IRONMAN 70.3 World Championship to take place in Oman, specifically in its capital of Muscat. Through this collaboration, Experience Oman...

Continue Reading
Exploring Quantica Tech's Innovative Quantic Bitcoin Initiative

Updated Category News Views 182

Introducing Quantic Bitcoin by Quantica Tech Quantica Tech, renowned for its innovations in quantum computing for blockchain, has embarked on an exciting project: Quantic Bitcoin (BTCQ). This initiative signifies a major leap towards integrating quantum computing capabilities into the decentralized finance landscape. With the development of a unique quantum...

Continue Reading
Exploring Integrity in NYC Real Estate Media Reporting

Updated Category News Views 227

Assessing the Reliability of Bisnow's NYC Real Estate Reporting In the fast-paced world of New York City's real estate market, the accuracy of information plays a crucial role for various stakeholders, including investors, lenders, and policy-makers. These groups rely heavily on precise reporting to navigate the complex and often unpredictable regulatory landscape....

Continue Reading
Citi Analysts Recommend Buying Microsoft After Share Pullback

Updated Category News Views 70

Citi Analysts Recommend Buying Microsoft After Share Pullback Recent insights from analysts at Citi suggest that investors should consider purchasing Microsoft (NASDAQ: MSFT) shares following a notable price drop. They believe this presents an opportunity, highlighting potential upside in the coming quarters for the tech giant. Understanding Microsoft’s Current...

Continue Reading